Angiotensin-converting enzyme inhibition delays pulmonary vascular neointimal formation.
暂无分享,去创建一个
D. Schuster | M. Botney | K. Okada | M. Bernstein | W. Zhang | Daniel P. Schuster | MITCHELL D. Botney | Kazushige Okada | Matthew L. Bernstein | Wei Zhang
[1] Wei Zhang,et al. Pulmonary hemodynamics modify the rat pulmonary artery response to injury. A neointimal model of pulmonary hypertension. , 1997, The American journal of pathology.
[2] R. Barst. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin. , 1997, Heart.
[3] L. Moons,et al. Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling. , 1996, Circulation.
[4] W. Parks,et al. Angiotensin converting enzyme expression in primary pulmonary hypertension. , 1996, American journal of respiratory and critical care medicine.
[5] J. Cooper,et al. Site-specific responses to monocrotaline-induced vascular injury: evidence for two distinct mechanisms of remodeling. , 1996, American journal of respiratory cell and molecular biology.
[6] D. Schuster,et al. The role of vascular injury and hemodynamics in rat pulmonary artery remodeling. , 1996, The Journal of clinical investigation.
[7] M. Hardenbrook,et al. Isolation of vascular smooth muscle cell cultures with altered responsiveness to the antiproliferative effect of heparin , 1996, Journal of cellular physiology.
[8] B. Groves,et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.
[9] M. Horiuchi,et al. Angiotensin II type 2 receptor mediates programmed cell death. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[10] R. Morishita,et al. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[11] N. Morrell,et al. Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension. , 1995, The American journal of physiology.
[12] N. Morrell,et al. Angiotensin converting enzyme expression is increased in small pulmonary arteries of rats with hypoxia-induced pulmonary hypertension. , 1995, The Journal of clinical investigation.
[13] T. Lüscher,et al. Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin1 receptors. , 1995, The Journal of clinical investigation.
[14] R. Prewitt,et al. Regulation of PDGF-A: a possible mechanism for angiotensin II-induced vascular growth. , 1995, The American journal of physiology.
[15] L. Gold,et al. Active Macrophage-Associated TGF-f3 Co-Localizes with Type I Procollagen Gene Expression in Atherosclerotic Human Pulmonary Arteries , 2007 .
[16] D. Vaughan,et al. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. , 1995, The Journal of clinical investigation.
[17] T. Unger,et al. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. , 1995, Pharmacological reviews.
[18] M. Paul,et al. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. , 1995, The Journal of clinical investigation.
[19] M. Frid,et al. Multiple phenotypically distinct smooth muscle cell populations exist in the adult and developing bovine pulmonary arterial media in vivo. , 1994, Circulation research.
[20] A. Desmoulière,et al. Characterization of rat aortic smooth muscle cells resistant to the antiproliferative activity of heparin following long‐term heparin treatment , 1994, Journal of cellular physiology.
[21] H. Rakugi,et al. Potential Importance of Tissue Angiotensin‐Converting Enzyme Inhibition in Preventing Neointima Formation , 1994, Circulation.
[22] S. Kagami,et al. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. , 1994, The Journal of clinical investigation.
[23] S. Schwartz,et al. Characterization of cloned aortic smooth muscle cells from young rats. , 1994, The American journal of pathology.
[24] A. Chobanian,et al. Angiotensin II induces fibronectin expression associated with cardiac fibrosis in the rat. , 1994, Circulation research.
[25] C. Molloy,et al. Angiotensin II induces delayed mitogenesis and cellular proliferation in rat aortic smooth muscle cells. Correlation with the expression of specific endogenous growth factors and reversal by suramin. , 1994, The Journal of clinical investigation.
[26] L. Gold,et al. Vascular remodeling in primary pulmonary hypertension. Potential role for transforming growth factor-beta. , 1994, American Journal of Pathology.
[27] O. Carretero,et al. Kallikrein release by vascular tissue. , 1993, The American journal of physiology.
[28] P. Delafontaine,et al. Angiotensin II regulates insulin-like growth factor I gene expression in vascular smooth muscle cells. , 1993, The Journal of biological chemistry.
[29] R. Mecham,et al. Active collagen synthesis by pulmonary arteries in human primary pulmonary hypertension. , 1993, The American journal of pathology.
[30] D. Stewart,et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.
[31] L. Chao,et al. Regulation of Kininogen Gene Expression and Localization in the Lung after Monocrotaline-Induced Pulmonary Hypertension in Rats , 1993, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[32] O. Carretero,et al. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. , 1993, Circulation research.
[33] M. Karnovsky,et al. Isolation of heparin-insensitive aortic smooth muscle cells. Growth and differentiation. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.
[34] P. Sever,et al. Abnormal growth regulation of vascular smooth muscle cells by heparin in patients with restenosis , 1993, The Lancet.
[35] R. Mecham,et al. Neointimal macrophages colocalize with extracellular matrix gene expression in human atherosclerotic pulmonary arteries. , 1993, The Journal of clinical investigation.
[36] C. Lambert,et al. Short- and long-term hemodynamic effects of captopril in patients with pulmonary hypertension and selected connective tissue disease. , 1992, Chest.
[37] M. Gillespie,et al. Angiotensin II and monocrotaline-induced pulmonary hypertension: effect of losartan (DuP 753), a nonpeptide angiotensin type 1 receptor antagonist. , 1992, The Journal of pharmacology and experimental therapeutics.
[38] G. Gibbons,et al. Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. , 1992, The Journal of clinical investigation.
[39] R. Mecham,et al. Extracellular matrix protein gene expression in atherosclerotic hypertensive pulmonary arteries. , 1992, The American journal of pathology.
[40] H. Yasuda,et al. Endothelin stimulates angiotensin I to angiotensin II conversion in cultured pulmonary artery endothelial cells. , 1990, Journal of molecular and cellular cardiology.
[41] A. Clowes,et al. Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells. , 1990, The American journal of pathology.
[42] S. Yohn,et al. An antifibrotic agent reduces blood pressure in established pulmonary hypertension in the rat. , 1990, Journal of applied physiology.
[43] B. Caleb,et al. Heparin inhibits c-fos and c-myc mRNA expression in vascular smooth muscle cells. , 1990, Cell regulation.
[44] A. Fishman,et al. 37. Acute Vasodilator Testing and Pharmacological Treatment of Primary Pulmonary Hypertension , 1990 .
[45] B. Groves,et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. , 1989, Circulation.
[46] H. Baumgartner,et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. , 1989, Science.
[47] H. O'brodovich,et al. Angiotensin II prevents hypoxic pulmonary hypertension and vascular changes in rat. , 1988, The American journal of physiology.
[48] F. Keeley,et al. Altered elastin and collagen synthesis associated with progressive pulmonary hypertension induced by monocrotaline. A biochemical and ultrastructural study. , 1988, Laboratory investigation; a journal of technical methods and pathology.
[49] M. Rabinovitch,et al. High-pressure pulsation of central and microvessel pulmonary artery endothelial cells. , 1988, The American journal of physiology.
[50] P. Chomczyński,et al. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.
[51] A. Padua,et al. Hemodynamic changes with enalapril in pulmonary arterial hypertension secondary to congenital heart disease. , 1987, Chest.
[52] T. Higenbottam,et al. Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin). , 1987, British heart journal.
[53] C. Ruppert,et al. Reduction of chronic hypoxic pulmonary hypertension in the rat by an inhibitor of collagen production. , 1987, The American review of respiratory disease.
[54] A. Molteni,et al. Monocrotaline-Induced Cardiopulmonary Damage in Rats: Amelioration by the Angiotensin-Converting Enzyme Inhibitor CL242817 , 1986, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[55] K. Stumpe,et al. Persistent hemodynamic and clinical improvement after captopril in patients with pulmonary hypertension. , 1986, Herz.
[56] A. Clowes,et al. Kinetics of Cellular Proliferation after Arterial Injury: IV. Heparin Inhibits Rat Smooth Muscle Mitogenesis and Migration , 1986, Circulation research.
[57] A. Molteni,et al. Monocrotaline-Induced Pulmonary Fibrosis in Rats: Amelioration by Captopril and Penicillamine , 1985, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[58] R. Soulen. Primary Pulmonary Hypertension: A Histopathologic Study of 80 Cases , 1985 .
[59] B. Brundage,et al. The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension. , 1985, Circulation.
[60] R. Rosenberg,et al. An antiproliferative heparan sulfate species produced by postconfluent smooth muscle cells , 1985, The Journal of cell biology.
[61] R. Trelstad,et al. Reduction of chronic hypoxic pulmonary hypertension in the rat by beta-aminopropionitrile. , 1984, Journal of applied physiology: respiratory, environmental and exercise physiology.
[62] R. Goldstein,et al. Activation of protein formation and cell division by bradykinin and des-Arg9-bradykinin. , 1984, The Journal of biological chemistry.
[63] R. Magorien,et al. Captopril in Primary Pulmonary Hypertension , 1983, Circulation.
[64] M. Karnovsky,et al. Inhibition of vascular smooth muscle cell growth by endothelial cell-derived heparin. Possible role of a platelet endoglycosidase. , 1982, The Journal of biological chemistry.
[65] R. Goldstein,et al. The effect and interaction of bradykinin and prostaglandins on protein and collagen production by lung fibroblasts. , 1982, The Journal of biological chemistry.
[66] R. Rosenberg,et al. Cultured endothelial cells produce heparinlike inhibitor of smooth muscle cell growth , 1981, The Journal of cell biology.
[67] M. Karnovsky,et al. Inhibition of Rat Arterial Smooth Muscle Cell Proliferation by Heparin: In Vivo Studies with Anticoagulant and Nonanticoagulant Heparin , 1980, Circulation research.
[68] A. Clowes,et al. Suppression by heparin of smooth muscle cell proliferation in injured arteries , 1977, Nature.
[69] D W Cushman,et al. Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. , 1971, Biochemical pharmacology.
[70] C. Wagenvoort,et al. Primary Pulmonary Hypertension: A Pathologic Study of the Lung Vessels in 156 Clinically Diagnosed Cases , 1970 .
[71] P. Wood. PULMONARY HYPERTENSION WITH SPECIAL REFERENCE TO THE VASOCONSTRICTIVE FACTOR* , 1958, British heart journal.
[72] J. Edwards,et al. The Pathology of Hypertensive Pulmonary Vascular Disease: A Description of Six Grades of Structural Changes in the Pulmonary Arteries with Special Reference to Congenital Cardiac Septal Defects , 1958, Circulation.
[73] M. A. Head,et al. Pathological Changes in Rats as a Result of Treatment with Monocrotaline , 1955, British Journal of Cancer.
[74] D. Dresdale,et al. Primary pulmonary hypertension. I. Clinical and hemodynamic study. , 1951, The American journal of medicine.
[75] H. Iwao,et al. [Vascular remodeling]. , 2000, Nihon rinsho. Japanese journal of clinical medicine.
[76] T. Matsusaka,et al. Biological functions of angiotensin and its receptors. , 1997, Annual review of physiology.
[77] E. Nabel,et al. Fibroblast growth factor stimulates angiotensin converting enzyme expression in vascular smooth muscle cells. Possible mediator of the response to vascular injury. , 1995, The Journal of clinical investigation.
[78] R. Klocke,et al. THE AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE , 1994 .
[79] M. Bernfield,et al. Endothelial heparan sulfate proteoglycan. I. Inhibitory effects on smooth muscle cell proliferation. , 1990, American journal of respiratory cell and molecular biology.
[80] K. Stenmark,et al. Abnormal alveolar cells in monocrotaline induced pulmonary hypertension. , 1983, Experimental lung research.